Elsevier,
Biomarkers in Neuropsychiatry, Volume 3, December 2020
Change point analysis can reveal when a biomarker starts to diverge from the pattern of normal aging. This paper analyzes several biomarkers from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to estimate the sequence and timing of their change points relative to a subsequent clinical diagnosis of mild cognitive impairment (MCI) in subjects initially considered cognitively normal (CN).
Elsevier, The Lancet Healthy Longevity, Volume 1, December 2020
Background: Circadian disturbances are commonly seen in people with Alzheimer's disease and have been reported in individuals without symptoms of dementia but with Alzheimer's pathology. We aimed to assess the temporal relationship between circadian disturbances and Alzheimer's progression. Methods: We did a prospective cohort study of 1401 healthy older adults (aged >59 years) enrolled in the Rush Memory and Aging Project (Rush University Medical Center, Chicago, IL, USA) who had been followed up for up to 15 years.
Elsevier,
Forensic Science International: Reports, Volume 2, December 2020, 100053
In this brief perspective piece, a rural sexual assault nurse examiner (SANE) program is described in the hopes that dissemination will lead to increased numbers of rural SANEs, increased reporting of sexual assaults in rural and underserved communities, increased prosecution rates of sexual assault perpetrators, and program sustainability through the provision of a nurse-centered approach to training and support. This article contributes SDGs 3, 5, 9, and 16.
Elsevier,
Forensic Science International: Reports, Volume 2, December 2020, 100089
Advancing SDGs 3, 5 and 16, this article discusses increased risk of family violence during COVID-19 pandemic and suggests that collaborations between human welfare and animal welfare agencies, expanding community partnerships, and informing the public of the great importance of reporting any concerns of abuse are all critical at this time.
Elsevier,
SLAS Discovery, Volume 25, Issue 10, December 2020, Pages 1174-1190
Animal models are used with increasing numbers in the late LO phase and particularly in the candidate selection phase for pharmacokinetic/pharmacodynamic (PK/PD) and efficacy, and then also used in regulatory required safety studies. Therefore, there are opportunities throughout the drug discovery process to incorporate more translationally predictive cellular models, or CIVMs, to both reduce animal use aligned to our 3Rs commitment (replacement, reduction, and refinement) and provide data that better translate to the clinic, which ultimately results in better medicines for patients.
